24 research outputs found

    Delinquent Daughters:Hollywood's war effort and the 'juvenile delinquency picture' cycle

    Get PDF
    This paper examines a short-lived cycle of ‘juvenile delinquency pictures’ that have been almost entirely ignored in scholarship on the teen film, perhaps in part because they focus on female rather than male youth. Whilst individually unremarkable, collectively these films were central to political debates about the role of Hollywood in wartime. This paper maps the widespread discursive struggles between Hollywood, the middlebrow press, industry regulators, and various government agencies over the production of this cycle. It moves on to analyse the New York reception of these films, highlighting how this ‘cycle of sensation’ was debated in relation to the very local contexts of New York's ‘bobby soxers’ and ‘victory girls’ and the strategies to police them in and around Times Square. It demonstrates that focusing on the localized and contested terrain of discourses surrounding historically situated media cycles reveals the complexity and local specificity required of micro-historical enquiry

    Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

    Get PDF
    Aims: The safety and efficacy of the novel selective cardiac myosin activator, omecamtiv mecarbil, in patients with heart failure with reduced ejection fraction (HFrEF) is tested in the Global Approach to Lowering Adverse Cardiac outcomes Through Improving Contractility in Heart Failure (GALACTIC‐HF) trial. Here we describe the baseline characteristics of participants in GALACTIC‐HF and how these compare with other contemporary trials. Methods and Results: Adults with established HFrEF, New York Heart Association functional class (NYHA) ≄ II, EF ≀35%, elevated natriuretic peptides and either current hospitalization for HF or history of hospitalization/ emergency department visit for HF within a year were randomized to either placebo or omecamtiv mecarbil (pharmacokinetic‐guided dosing: 25, 37.5 or 50 mg bid). 8256 patients [male (79%), non‐white (22%), mean age 65 years] were enrolled with a mean EF 27%, ischemic etiology in 54%, NYHA II 53% and III/IV 47%, and median NT‐proBNP 1971 pg/mL. HF therapies at baseline were among the most effectively employed in contemporary HF trials. GALACTIC‐HF randomized patients representative of recent HF registries and trials with substantial numbers of patients also having characteristics understudied in previous trials including more from North America (n = 1386), enrolled as inpatients (n = 2084), systolic blood pressure < 100 mmHg (n = 1127), estimated glomerular filtration rate < 30 mL/min/1.73 m2 (n = 528), and treated with sacubitril‐valsartan at baseline (n = 1594). Conclusions: GALACTIC‐HF enrolled a well‐treated, high‐risk population from both inpatient and outpatient settings, which will provide a definitive evaluation of the efficacy and safety of this novel therapy, as well as informing its potential future implementation
    corecore